GSK GlaxoSmithKline PLC
- Price as of: Dec 19, 10:24 PM EST
- Drug manufacturers - major
GSK Stock Dividend DataAdd GSK to Watchlist
GSK Daily Snapshot
- Quote Time:
- Dec 19, 10:24 PM
- Today's Volume:
- Open Price:
- Day's Range:
- $42.98 - $43.58
- Previous Close:
- 52 Week Low / High:
- $41.29 - $56.73
- Percent Off 52 Week High:
GSK Dividend Growth History
Last 5 Yrs
Last 3 Yrs
|Reveal More Dividend Growth History for GSK||6.4%||3.9%||1 year|
GSK Dividend History
|Payout Amount||Declared Date||Ex-Dividend Date||Record Date||Pay Date ▼||Qualified Dividend?||Payout Type||Frequency|
GSK Company Profile
GlaxoSmithKline (GSK) is a global healthcare group. The company focuses on the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. GSK was founded in 1999, and is based in the UK. In April 2014, GSK sold its cancer-drug business to Novartis for $14.5 billion and acquired Novartis’s vaccines business for $7.1 billion, along with creating a new consumer health business by operating a joint venture. GSK operates in a highly competitive business, and relies on patent protection and market exclusivity for its products to achieve high levels of profitability. GSK’s success is also dependent on its ability to continuously develop new pharmaceutical products. GSK has been paying a dividend since 2001 and has been increasing it consistently since 2009, which is when it last cut its payout. GSK pays its dividends quarterly.
GlaxoSmithKline PLC News
Jul 31, 2014Ex-dividend dates are very important to dividend investors, since you must purchase a stock prior to its ex-dividend date in order to receive its...
Jul 31, 2014Here at Dividend.com, we constantly emphasize the importance of strong fundamentals when it comes to making any investment decision. However, with...
Apr 4, 2014Following news that UK-based GlaxoSmithKline plc (GSK) bribed doctors and officials to improve sales in China, the drugmaker announced that it...
GlaxoSmithKline to Sell Thrombosis Brands for $1.13B (GSK)Sep 30, 2013GlaxoSmithKline plc (GSK) announced on Monday that it has agreed to sell its thrombosis drugs, Arixtra and Fraxiparine, and its Notre-Dame de Bondeville manufacturing facility for $1.13 billion. The British pharmaceutical company will sell both drug brands along with its manufacturing facility to The Aspen Group for £700 million or $1.13 billion in cash. This sale will allow GSK to focus on products with higher growth potential. GSK Chief Strategy Officer David Redfern commented: "Arixtra and Fraxiparine are established products that have consistently delivered strong revenues. However, our focus is on delivering an unprecedented late-stage pipeline and preparing for the launch of approved medicines. Aspen is a long-term partner of GSK and will be able to dedicate the resources that these products deserve to take them forward." GlaxoSmithKline shares were mostly flat during pre-market trading Monday. The stock is up 16% YTD.Expand to read the full story
GlaxoSmithKline Upgraded to "Neutral" at JP Morgan (GSK)Aug 14, 2013JP Morgan reported on Wednesday that it has upgraded healthcare company GlaxoSmithKline plc (GSK) . The firm has raised its rating on GSK to "Neutral" as analysts see upcoming catalysts balancing out risk. GlaxoSmithKline shares were up 29 cents, or 0.56%, during pre-market trading Wednesday. The stock is up 20% YTD. The Bottom Line Shares of GlaxoSmithKline plc (GSK) have a 4.25% yield based on Tuesday's closing price of $52.01. GlaxoSmithKline plc (GSK) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.4 out of 5 stars. Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.Expand to read the full story
JP Morgan Gets Bearish on GlaxoSmithKline; Says 2013 Earnings are at Risk (GSK)Aug 22, 2012U.K.-based pharmaceutical giant GlaxoSmithKline plc (GSK) on Wednesday caught a big downgrade from analysts at JP Morgan. The firm slashed its rating on GSK from "Neutral" to "Underweight," noting worries about the company's upcoming earnings. A JP Morgan analyst commented, "With material risk to 2013 earnings, no imminent positive catalysts, and almost no upside to our new PT, we downgrade to Underweight. GSK is entering an investment phase. After reassessing the investment required to execute on the pipeline, already taken for granted by consensus, we now expect Operating margins to contract, rather than expand in 2013, and we now forecast a 2013 Operating margin 200bps below consensus. We see earnings risk in 2013, with material Operating profit and earnings growth unlikely for at least a year further out than is currently forecast by consensus (which expects topline growth and margin expansion in 2013)." GlaxoSmithKline shares fell 53 cents, or -1.2%, in premarket trading Wednesday. The Bottom Line Shares of GlaxoSmithKline plc (GSK) have a 4.78% dividend yield, based on last night's closing stock price of $46.07. The stock has technical support in the $43-$44 price area. If the shares can firm up, we see overhead resistance around the $48-$50 price levels. GlaxoSmithKline plc (GSK) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.4 out of 5 stars. Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.Expand to read the full story
Jan 9, 2012These were some of the biggest dividend stock performers on the upside and the downside in today's market action. Highlights Acuity Brands...
Dec 9, 2011These were some of the biggest dividend stock performers on the upside and the downside in today's market action. Highlights Deutsche Bank...
FDA Approves GlaxoSmithKline's Lupus Treatment (GSK)Mar 10, 2011British pharmaceutical giant GlaxoSmithKline plc (GSK) got some welcome news from the FDA late Wednesday night, as the federal regulator approved a lupus treatment drug that GSK has been pegged to market. The drug, called Benlysta, was developed by U.S.-based Human Genome Sciences (HGSI) and will be marketed and sold by GSK. Benlysta is the first lupus treatment drug approved in the U.S. since 1955. Lupus, a potentially fatal autoimmune disease, affects 1.5 million Americans and 5 million people worldwide, according to the Lupus Foundation of America. GlaxoSmithKline shares rose 20 cents, or +0.5%, in premarket trading Thursday. The Bottom Line Shares of GlaxoSmithKline (GSK) have a 6.38% dividend yield, based on last night's closing stock price of $38.58. The stock has technical support in the $36 price area. If the shares can firm up, we see overhead resistance around the $40-$42 price levels. GlaxoSmithKline plc (GSK) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.4 out of 5 stars. Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.Expand to read the full story
Feb 7, 2011These were some of the biggest dividend stock performers on the upside and the downside in today's market action. Highlights Beckman Coulter...